MTORC1 and MTORC2 Selectively Regulate CD8⁺ T Cell Differentiation
Overview
Authors
Affiliations
Activation of mTOR-dependent pathways regulates the specification and differentiation of CD4+ T effector cell subsets. Herein, we show that mTOR complex 1 (mTORC1) and mTORC2 have distinct roles in the generation of CD8+ T cell effector and memory populations. Evaluation of mice with a T cell-specific deletion of the gene encoding the negative regulator of mTORC1, tuberous sclerosis complex 2 (TSC2), resulted in the generation of highly glycolytic and potent effector CD8+ T cells; however, due to constitutive mTORC1 activation, these cells retained a terminally differentiated effector phenotype and were incapable of transitioning into a memory state. In contrast, CD8+ T cells deficient in mTORC1 activity due to loss of RAS homolog enriched in brain (RHEB) failed to differentiate into effector cells but retained memory characteristics, such as surface marker expression, a lower metabolic rate, and increased longevity. However, these RHEB-deficient memory-like T cells failed to generate recall responses as the result of metabolic defects. While mTORC1 influenced CD8+ T cell effector responses, mTORC2 activity regulated CD8+ T cell memory. mTORC2 inhibition resulted in metabolic reprogramming, which enhanced the generation of CD8+ memory cells. Overall, these results define specific roles for mTORC1 and mTORC2 that link metabolism and CD8+ T cell effector and memory generation and suggest that these functions have the potential to be targeted for enhancing vaccine efficacy and antitumor immunity.
Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting.
Qiang M, Chen Z, Liu H, Dong J, Gong K, Zhang X Front Pharmacol. 2025; 16:1516583.
PMID: 40041495 PMC: 11877449. DOI: 10.3389/fphar.2025.1516583.
Lysosomal NKG7 restrains mTORC1 activity to promote CD8 T cell durability and tumor control.
Ham H, Hirdler J, Bihnam D, Mao Z, Gicobi J, Macedo B Nat Commun. 2025; 16(1):1628.
PMID: 39952956 PMC: 11829009. DOI: 10.1038/s41467-025-56931-6.
Immunosenescence, Physical Exercise, and their Implications in Tumor Immunity and Immunotherapy.
Yu X, Pei W, Li B, Sun S, Li W, Wu Q Int J Biol Sci. 2025; 21(3):910-939.
PMID: 39897036 PMC: 11781184. DOI: 10.7150/ijbs.100948.
Fatty acid metabolism: A new target for nasopharyngeal carcinoma therapy.
Li J, Ping P, Li Y, Xu X Chin J Cancer Res. 2025; 36(6):652-668.
PMID: 39802901 PMC: 11724175. DOI: 10.21147/j.issn.1000-9604.2024.06.05.
Immune imbalance in Lupus Nephritis: The intersection of T-Cell and ferroptosis.
Fan Y, Ma K, Lin Y, Ren J, Peng H, Yuan L Front Immunol. 2024; 15:1520570.
PMID: 39726588 PMC: 11669548. DOI: 10.3389/fimmu.2024.1520570.